The independent medical news service

Trastuzumab deruxtecan achieves durable responses in individuals who have received prior treatment for metastatic non-small-cell lung cancer harboring HER2 mutations, suggests the DESTINY-Lung01 trial.

Individuals with unresectable locally advanced non-small-cell lung cancer and no progression after chemoradiotherapy could benefit from the addition of the CD73 inhibitor oleclumab or the NKG2A-targeted agent monalizumab to consolidation durvalumab, suggest phase 2 results.

Click through to read more about this approval

The addition of bevacizumab to erlotinib does not improve the overall survival of treatment-naïve patients with advanced non-small-cell lung cancer harboring an activating EGFR mutation, NEJ026 study data show.

Strategies to improve flexibility in clinical trials may improve enrollment rates during and after the COVID-19 pandemic, according to a study presented at the IASLC 2021 World Conference on Lung Cancer.

Assessing circulating tumor DNA levels prior to initiating neoadjuvant chemoimmunotherapy for locally advanced non-small-cell lung cancer could help to identify patients likely to derive long-term benefit from treatment, suggest exploratory data.